AIM: To assess the biological significance of vascular endothelial growth factor (VEGF) A, VEGF receptor (Flk-1) and cyclooxygenase 2 (COX2) expression with respect to microvessel density (MVD), proliferative activity (Ki-67), expression of p53 and clinical presentation in a large cohort of nodal B cell lymphomas. METHODS: An immunohistochemical and morphometric study was performed on a validated tissue microarray containing 271 B cell lymphoma specimens, 197 of which included follow-up data. Statistical assessment was done by Pearson's chi(2) test, Spearman's rank correlation coefficient, analysis of variance and survival analysis. RESULTS: 266 (98%) cases were evaluable. Strong VEGF expression was observed in only 20 diffuse large B cell lymphomas (DLBCLs). Flk-1 and COX2 were expressed in 53 and 21 cases, respectively, mainly in DLBCLs, follicular lymphoma (FL) grade 3 and mantle cell lymphomas (MCLs), in a low proportion of cells. MVD decreased in the following order: DLBCLs, FLs, MCLs and small lymphocytic lymphomas/chronic lymphocytic leukaemia (SLL/CLLs). VEGF expression correlated with Ki-67, p53 and COX2 expression in the whole cohort and in DLBCLs. Flk-1 expression correlated with Ki-67 in the cohort and in SLL/CLL and FL grade 1 and 2. COX2 expression correlated with Ki-67 and p53. The analysed angiogenesis parameters did not correlate with clinical parameters or survival. CONCLUSIONS: Angiogenesis plays a differential role in various B cell lymphomas. Aggressive lymphomas express the potential molecular therapeutic targets VEGF and COX2, and have higher MVD. In a few low proliferation-fraction lymphomas, Flk-1 might have a role in proliferative advantage. Therapeutic strategies aimed at angiogenesis should take into account lymphoma heterogeneity.
AIM: To assess the biological significance of vascular endothelial growth factor (VEGF) A, VEGF receptor (Flk-1) and cyclooxygenase 2 (COX2) expression with respect to microvessel density (MVD), proliferative activity (Ki-67), expression of p53 and clinical presentation in a large cohort of nodal B cell lymphomas. METHODS: An immunohistochemical and morphometric study was performed on a validated tissue microarray containing 271 B cell lymphoma specimens, 197 of which included follow-up data. Statistical assessment was done by Pearson's chi(2) test, Spearman's rank correlation coefficient, analysis of variance and survival analysis. RESULTS: 266 (98%) cases were evaluable. Strong VEGF expression was observed in only 20 diffuse large B cell lymphomas (DLBCLs). Flk-1 and COX2 were expressed in 53 and 21 cases, respectively, mainly in DLBCLs, follicular lymphoma (FL) grade 3 and mantle cell lymphomas (MCLs), in a low proportion of cells. MVD decreased in the following order: DLBCLs, FLs, MCLs and small lymphocytic lymphomas/chronic lymphocytic leukaemia (SLL/CLLs). VEGF expression correlated with Ki-67, p53 and COX2 expression in the whole cohort and in DLBCLs. Flk-1 expression correlated with Ki-67 in the cohort and in SLL/CLL and FL grade 1 and 2. COX2 expression correlated with Ki-67 and p53. The analysed angiogenesis parameters did not correlate with clinical parameters or survival. CONCLUSIONS: Angiogenesis plays a differential role in various B cell lymphomas. Aggressive lymphomas express the potential molecular therapeutic targets VEGF and COX2, and have higher MVD. In a few low proliferation-fraction lymphomas, Flk-1 might have a role in proliferative advantage. Therapeutic strategies aimed at angiogenesis should take into account lymphoma heterogeneity.
Authors: Eunice S Wang; Julie Teruya-Feldstein; Yan Wu; Zhenping Zhu; Daniel J Hicklin; Malcolm A S Moore Journal: Blood Date: 2004-07-06 Impact factor: 22.113
Authors: Barbara Pro; Anas Younes; Maher Albitar; Nam H Dang; Felipe Samaniego; Jorge Romaguera; Peter McLaughlin; Fredrick B Hagemeister; Maria A Rodriguez; Marilyn Clemons; Fernando Cabanillas Journal: Cancer Date: 2004-03-15 Impact factor: 6.860
Authors: Pavla Veselá; Zbyněk Tonar; David Sálek; Samuel Vokurka; Marek Trněný; Roman Kodet; Mojmír Moulis; Petra Kašparová; Zdeňka Vernerová; Zuzana Velenská; Jan Stříteský; Michal Michal; Ludmila Boudová Journal: Virchows Arch Date: 2014-07-22 Impact factor: 4.064
Authors: Teresa M Cardesa-Salzmann; Luis Colomo; Gonzalo Gutierrez; Wing C Chan; Dennis Weisenburger; Fina Climent; Eva González-Barca; Santiago Mercadal; Leonor Arenillas; Sergio Serrano; Ray Tubbs; Jan Delabie; Randy D Gascoyne; Joseph M Connors; Jose L Mate; Lisa Rimsza; Rita Braziel; Andreas Rosenwald; Georg Lenz; George Wright; Elaine S Jaffe; Louis Staudt; Pedro Jares; Armando López-Guillermo; Elias Campo Journal: Haematologica Date: 2011-05-05 Impact factor: 9.941
Authors: P J Simpson-Haidaris; S J Pollock; S Ramon; N Guo; C F Woeller; S E Feldon; R P Phipps Journal: PPAR Res Date: 2010-02-28 Impact factor: 4.964
Authors: Kathrin Rupertus; Gudrun C Y Haberl; Claudia Scheuer; Michael D Menger; Martin K Schilling; Otto Kollmar Journal: J Oncol Date: 2011-10-02 Impact factor: 4.375